American Regent Expands Pain Injection Vial Recall

Law360, New York (November 4, 2009, 3:51 PM EST) -- American Regent on Wednesday expanded its voluntary recall of Ketorolac Tromethamine Injection vials to the 15 mg/mL dose due to the presence of particulate matter, the company and the U.S. Food and Drug Administration said.

The drug is described as a nonsteroidal anti-inflammatory medication used short-term for the treatment of acute pain.

This recall came in addition to a voluntary recall initiated on Oct. 16 when the Shirley, N.Y.-based Luitpold Pharmaceuticals Inc. subsidiary recalled unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL due to the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.